Form 8-K Arcutis Biotherapeutics, For: May 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho
May 15, 2024 5:18 AM EDTMizuho analyst Uy Ear raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $18.00 (from $17.00) while maintaining a Buy rating.
The analyst comments "1Q24 was strong, with Zoryve (Cream + Foam) beating our above-Consensus forecasts driven by significantly better-than-expected gross-to-nets (GtN),... More
